Volume 18, Number 5—May 2012
Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru
|Characteristic||Univariate OR† (95% CI)||p value||Multivariate OR† (95% CI)‡||p value|
|Age, per 10-y increase||0.89 (0.81–0.99)||0.034||0.90 (0.81–1.00)||0.046|
|Male sex||1.09 (0.81–1.46)||0.58||1.05 (0.78–1.43)||0.74|
|Negative sputum smear test results||2.05 (1.37–3.08)||<0.001||2.11 (1.40–3.19)||<0.001|
|HIV infection||0.59 (0.31–1.13)||0.11||0.52 (0.27–1.00)||0.049|
|History of TB treatment||2.38 (1.78–3.18)||<0.001||2.41 (1.80–3.23)||<0.001|
|Known household contact with persons with MDR TB||1.18 (0.89–1.57)||0.25||1.08 (0.81–1.44)||0.59|
*MDR, multidrug resistant; TB, tuberculosis; DST, drug-susceptibility testing; OR, odds ratio.
†ORs represent risk for MDR TB conditional on receiving DST. For example, even if household contact with persons with MDR TB is marginally associated with increased risk for MDR TB, the observed association would likely be attenuated when the analysis is restricted to those who received DST because household contact with persons with MDR TB is an accepted criterion for ordering DST.
‡Adjusted for all other variables listed.
- Page created: April 05, 2012
- Page last updated: April 12, 2012
- Page last reviewed: April 12, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)